#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bronchopulmonary aspergillosis Cytokine release syndrome Aplastic anaemia Pemphigoid Optic ischaemic neuropathy Malignant melanoma Pemphigus Hyperphagia Juvenile chronic myelomonocytic leukaemia Squamous cell carcinoma of the hypopharynx Astrocytoma Epstein-Barr virus associated lymphoproliferative disorder Systemic sclerosis pulmonary Exudative retinopathy Peripheral T-cell lymphoma unspecified More trials…

    Learn about Rare Diseases

    Angiosarcoma – Basic Information Glomerulonephritis rapidly progressive – Life with Disease Combined immunodeficiency – Diagnostics Soft tissue sarcoma Paroxysmal nocturnal haemoglobinuria – Life with Disease Prader-Willi syndrome – Diagnostics Waldenstrom’s macroglobulinaemia recurrent Lennox-Gastaut syndrome – Trials in Disease Systemic mastocytosis Tuberous sclerosis complex – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cetirizine Dihydrochloride Quinidine Sulfate Technetium (99Mtc) Mbs2320 Cocarboxylase Tetrahydrate Bleomycin Sulfate Ph. Eur. Quinapril Hydrochloride ALE.P03 SRSD107 NERANDOMILAST Ovolecithin Gefitinib Ioversol Acetylsalicylic Acid Vorinostat Ieramilimab BMS-986470 Sodium Oxybate ATOVAQUONE Ganciclovir More therapies…

    Learn about Your Condition

    Endometrial cancer recurrent Pancreatitis acute Mucopolysaccharidosis II Proteinuria Papilloma viral infection Neuropathy peripheral Renal cell carcinoma stage IV Sarcoma Diabetic foot infection Rectosigmoid cancer Perthes disease Post procedural hypotension Joint stabilisation Placenta praevia Eyelid ptosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliero Universitaria Ospedali Riuniti…

Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi

Via Filippo Corridoni 11, Ancona, 60123, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    Austria Czechia Denmark Finland France Germany +7

  • Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Calcium Levofolinate
    • Bevacizumab
    • Cetuximab
    Italy Spain

  • Study of Faricimab Treatment Given Every 24 Weeks in Patients with Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Faricimab
    France Germany Italy Spain

  • Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Treosulfan
    • Daunorubicin Hydrochloride
    • Gemtuzumab Ozogamicin
    Italy

  • Study on Avelumab and Cetuximab for Patients with Metastatic Colorectal Cancer Who Have Previously Received Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    Italy

  • Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hairy cell leukaemia
    Investigated Drugs:
    • Vemurafenib
    • Cladribine
    • Rituximab
    Italy

  • Study Comparing Atezolizumab Alone and Atezolizumab with Bevacizumab for First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    Italy

  • Study of Nivolumab for Early Stage Hodgkin Lymphoma in Patients with Good Prognosis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Nivolumab
    Italy Poland Spain

  • Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Busulfan
    • Azacitidine
    Italy

  • Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid for Patients with Atrial Fibrillation Undergoing Left Atrial Appendage Closure

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    Italy
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!